度伐利尤单抗治疗复发或转移性头颈部鳞状细胞癌:一项单臂II期研究结果,纳入肿瘤细胞PD-L1表达≥25%且含铂化疗后进展的患者
HAWK研究为国际多中心单臂II期试验,评估度伐利尤单抗单药治疗PD-L1高表达(TC≥25%)的铂类难治性复发/转移性头颈部鳞状细胞癌。可评估患者客观缓解率为16.2%,HPV阳性者29.4%,HPV阴性者10.9%;中位无进展生存期2.1个月,中位总生存期7.1个月;安全性可接受。
要点
- PD-L1高表达(TC≥25%)铂类难治性复发/转移性头颈部鳞癌患者客观缓解率为16.2%。
- HPV阳性患者客观缓解率29.4%,HPV阴性患者10.9%,为事后分析中的数值差异。
- 治疗相关不良事件任何级别57.1%,≥3级8.0%,无致死性事件。
核心结论
- 度伐利尤单抗在PD-L1高表达复发/转移性头颈部鳞癌患者中显示出抗肿瘤活性且安全性可接受,支持其在一线和二线治疗中开展III期试验评估。
- 事后分析中,HPV阳性患者较HPV阴性患者有数值上更高的缓解率和生存。
研究设计与样本
- 国际多中心单臂II期HAWK研究(NCT02207530),评估度伐利尤单抗单药治疗铂类难治性复发/转移性头颈部鳞状细胞癌。
- 纳入免疫治疗初治、经VENTANA PD-L1(SP263)检测确认肿瘤细胞PD-L1表达≥25%的患者,给予度伐利尤单抗10 mg/kg静脉注射每2周一次,最长12个月。
- 主要终点为客观缓解率;次要终点包括无进展生存期和总生存期;可评估患者111例,接受治疗患者112例。
主要发现
- 可评估患者(n=111)客观缓解率为16.2%(95%CI 9.9-24.4)。
- HPV阳性患者客观缓解率为29.4%(95%CI 15.1-47.5),HPV阴性患者为10.9%(95%CI 4.5-21.3)。
- 接受治疗患者(n=112)中位无进展生存期为2.1个月(95%CI 1.9-3.7),中位总生存期为7.1个月(95%CI 4.9-9.9)。
- 12个月无进展生存率为14.6%(95%CI 8.5-22.1),12个月总生存率为33.6%(95%CI 24.8-42.7)。
- 治疗相关不良事件任何级别发生率为57.1%,≥3级为8.0%,无致死性事件;数据截止时24.1%的患者仍在治疗或随访中。
临床怎么用
- 作者认为度伐利尤单抗在PD-L1高表达复发/转移性头颈部鳞癌中显示抗肿瘤活性且安全性可接受,支持其在一线和二线治疗中开展III期试验评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) progressing on platinum-based chemotherapy have poor prognoses and limited therapeutic options. Programmed cell death-1 (PD-1) and its ligand 1 (PD-L1) are frequently upregulated in HNSCC. The international, multi-institutional, single-arm, phase II HAWK study (NCT02207530) evaluated durvalumab monotherapy, an anti-PD-L1 monoclonal antibody, in PD-L1-high patients with platinum-refractory R/M HNSCC. PATIENTS AND METHODS: Immunotherapy-naïve patients with confirmed PD-L1-high tumour cell expression (defined as patients with ≥25% of tumour cells expressing PD-L1 [TC ≥ 25%] using the VENTANA PD-L1 [SP263] Assay) received durvalumab 10 mg/kg intravenously every 2 weeks for up to 12 months. The primary end-point was objective response rate; secondary end-points included progression-free survival (PFS) and overall survival (OS). RESULTS: Among evaluable patients (n = 111), objective response rate was 16.2% (95% confidence interval [CI], 9.9-24.4); 29.4% (95% CI, 15.1-47.5) for human papillomavirus (HPV)-positive patients and 10.9% (95% CI, 4.5-21.3) for HPV-negative patients. Median PFS and OS for treated patients (n = 112) was 2.1 months (95% CI, 1.9-3.7) and 7.1 months (95% CI, 4.9-9.9); PFS and OS at 12 months were 14.6% (95% CI, 8.5-22.1) and 33.6% (95% CI, 24.8-42.7). Treatment-related adverse events were 57.1% (any grade) and 8.0% (grade ≥3); none led to death. At data cut-off, 24.1% of patients remained on treatment or in follow-up. CONCLUSION: Durvalumab demonstrated antitumour activity with acceptable safety in PD-L1-high patients with R/M HNSCC, supporting its ongoing evaluation in phase III trials in first- and second-line settings. In an ad hoc analysis, HPV-positive patients had a numerically higher response rate and survival than HPV-negative patients.
引用
- Zandberg DP, Algazi AP, Jimeno A, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2018. PMID: 30576970. doi:10.1016/j.ejca.2018.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。